Leerink Swann lowered shares of Spark Therapeutics (NASDAQ:ONCE) from an outperform rating to a market perform rating in a research report report published on Tuesday, Marketbeat.com reports. They currently have $49.00 price target on the biotechnology company’s stock. Leerink Swann also issued estimates for Spark Therapeutics’ Q1 2018 earnings at ($1.75) EPS, Q2 2018 earnings at ($1.47) EPS, Q3 2018 earnings at ($1.21) EPS, FY2019 earnings at ($2.90) EPS and FY2020 earnings at ($2.57) EPS.

Other equities research analysts also recently issued reports about the stock. BMO Capital Markets set a $89.00 target price on shares of Spark Therapeutics and gave the stock a buy rating in a research report on Tuesday, October 10th. Cowen reaffirmed a buy rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Jefferies Group reaffirmed a buy rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Cantor Fitzgerald reaffirmed a buy rating and issued a $105.00 price objective (up from $94.00) on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group reaffirmed a buy rating and issued a $111.00 price objective on shares of Spark Therapeutics in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the stock. Spark Therapeutics has a consensus rating of Buy and a consensus price target of $76.19.

Shares of Spark Therapeutics (NASDAQ ONCE) opened at $46.37 on Tuesday. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.11). The business had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company’s revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.07) earnings per share. equities research analysts predict that Spark Therapeutics will post -7.6 earnings per share for the current year.

In other Spark Therapeutics news, insider Katherine A. High sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total value of $430,800.00. Following the transaction, the insider now directly owns 215,000 shares in the company, valued at $18,524,400. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Daniel Faga sold 1,500 shares of the business’s stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the transaction, the insider now owns 1,500 shares in the company, valued at $127,500. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,068,809 shares of company stock worth $89,809,385. Corporate insiders own 7.30% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ONCE. Teachers Advisors LLC boosted its stake in Spark Therapeutics by 1.9% in the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after acquiring an additional 650 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Spark Therapeutics by 81.6% in the second quarter. Russell Investments Group Ltd. now owns 25,228 shares of the biotechnology company’s stock valued at $1,507,000 after acquiring an additional 11,335 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Spark Therapeutics by 8.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 94,920 shares of the biotechnology company’s stock valued at $5,671,000 after acquiring an additional 7,169 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Spark Therapeutics in the second quarter valued at about $829,000. Finally, Rhumbline Advisers boosted its stake in Spark Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 26,278 shares of the biotechnology company’s stock valued at $1,570,000 after acquiring an additional 3,626 shares during the last quarter. Hedge funds and other institutional investors own 94.94% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.watchlistnews.com/spark-therapeutics-once-stock-rating-lowered-by-leerink-swann/1767779.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.